Literature DB >> 20975379

Malignant pleural mesothelioma: a population-based study of survival.

Michael T Milano1, Hong Zhang.   

Abstract

INTRODUCTION: This study characterizes the overall survival (OS) and variables affecting OS in patients with malignant pleural mesothelioma.
METHODS: A total of 9701 patients with malignant pleural mesothelioma, diagnosed from 1973 to 2006, were retrospectively analyzed using the population-based surveillance, epidemiology, and end results database.
RESULTS: The 6-month, 1-year, and 5-year OS were 55, 33, and 5%, respectively. Significantly adverse prognostic factors from univariate analyses included older age, male gender, higher tumor grade, nonepithelioid histology, higher stage, no cancer-directed surgery, and no radiotherapy. Race was not significant. Patients undergoing cancer-directed surgery and radiotherapy, when grouped by stage, histology, or grade, had the best median survival (versus radiotherapy or surgery alone or no surgery/radiotherapy). From Cox proportional hazards analyses, grade (range, 1-4) was associated with a hazard ratio (HR) of >1.5 (p < 0.0001), and not undergoing cancer-directed surgery was associated with a HR of >1.4 (p < 0.0001). Male gender and older age were also significantly adverse factors. Tumor histology (HR = 1.5) and nonlocalized stage (HR = 1.3) were significant in a Cox model omitting tumor grade. With grade and histology included in the Cox model, the HRs of histology and stage were of smaller magnitude and not significant.
CONCLUSIONS: From a population-based registry analysis of patients with malignant pleural mesothelioma, tumor grade and cancer-directed surgery seem to have the greatest impact on OS. Although being amenable to surgery likely reflects more indolent disease and/or better performance status and cardiopulmonary function, the significantly favorable impact of surgery, accounting for tumor grade, histology, and stage, may reflect a therapeutic benefit.

Entities:  

Mesh:

Year:  2010        PMID: 20975379     DOI: 10.1097/JTO.0b013e3181f1cf2b

Source DB:  PubMed          Journal:  J Thorac Oncol        ISSN: 1556-0864            Impact factor:   15.609


  51 in total

1.  Early mesothelioma revisited.

Authors:  Seiki Hasegawa
Journal:  Int J Clin Oncol       Date:  2012-01-11       Impact factor: 3.402

2.  Racial Disparities in Treatment Patterns and Survival Among Surgically Treated Malignant Pleural Mesothelioma Patients.

Authors:  Naomi Alpert; Maaike van Gerwen; Meredith Steinberg; Nisha Ohri; Raja Flores; Emanuela Taioli
Journal:  J Immigr Minor Health       Date:  2020-12

3.  Minor regression and long-time survival (56 months) in a patient with malignant pleural mesothelioma under Viscum album and Helleborus niger extracts-a case report.

Authors:  Paul G Werthmann; Gerhard Saltzwedel; Gunver S Kienle
Journal:  J Thorac Dis       Date:  2017-12       Impact factor: 2.895

Review 4.  Immunotherapy for malignant pleural mesothelioma: current status and future directions.

Authors:  Jordan Dozier; Hua Zheng; Prasad S Adusumilli
Journal:  Transl Lung Cancer Res       Date:  2017-06

5.  Radical surgery for malignant pleural mesothelioma: have we identified the appropriate selection tools?

Authors:  Nico van Zandwijk; Glen Reid; Anthony Linton; Steven Kao
Journal:  Ann Cardiothorac Surg       Date:  2012-11

Review 6.  Is there a role for immunotherapy in malignant pleural mesothelioma?

Authors:  Alfredo Tartarone; Rosa Lerose; Michele Aieta
Journal:  Med Oncol       Date:  2018-05-29       Impact factor: 3.064

Review 7.  Guidelines for the diagnosis and treatment of malignant pleural mesothelioma.

Authors:  Nico van Zandwijk; Christopher Clarke; Douglas Henderson; A William Musk; Kwun Fong; Anna Nowak; Robert Loneragan; Brian McCaughan; Michael Boyer; Malcolm Feigen; David Currow; Penelope Schofield; Beth Ivimey Nick Pavlakis; Jocelyn McLean; Henry Marshall; Steven Leong; Victoria Keena; Andrew Penman
Journal:  J Thorac Dis       Date:  2013-12       Impact factor: 2.895

8.  Prognostic factors of survival in patients with malignant pleural mesothelioma: an analysis of the National Cancer Database.

Authors:  Maaike Van Gerwen; Naomi Alpert; Andrea Wolf; Nisha Ohri; Erik Lewis; Kenneth E Rosenzweig; Raja Flores; Emanuela Taioli
Journal:  Carcinogenesis       Date:  2019-06-10       Impact factor: 4.944

9.  A Novel Prospective Study Assessing the Combination of Photodynamic Therapy and Proton Radiation Therapy: Safety and Outcomes When Treating Malignant Pleural Mesothelioma.

Authors:  Stephanie R Rice; Yun R Li; Theresa M Busch; Michele M Kim; Sally McNulty; Andrea Dimofte; Timothy C Zhu; Keith A Cengel; Charles B Simone
Journal:  Photochem Photobiol       Date:  2018-12-28       Impact factor: 3.421

10.  Patterns of failure, toxicity, and survival after extrapleural pneumonectomy and hemithoracic intensity-modulated radiation therapy for malignant pleural mesothelioma.

Authors:  Daniel R Gomez; David S Hong; Pamela K Allen; James S Welsh; Reza J Mehran; Anne S Tsao; Zhongxing Liao; Stephen D Bilton; Ritsuko Komaki; David C Rice
Journal:  J Thorac Oncol       Date:  2013-02       Impact factor: 15.609

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.